SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Ocugen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2021 - (OCGN)

July 16, 2021 5:44 PM EDT | Source: Gross Law Firm

New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGEN).

Shareholders who purchased shares of OCGN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/ocugen-inc-loss-submission-form/?id=17730&from=5

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7093/90537_445226_logo.jpg

CLASS PERIOD : February 2, 2021 to June 10, 2021

ALLEGATIONS : The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90537

info